Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.
Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
A drug that suppresses the immune system and reduces inflammation has been shown to be effective in treating lung disease associated with the devastating connective tissue disease scleroderma, according to results presented at the American Thoracic Society International Conference on May 23.
The chemotherapy regimen of doxorubicin plus docetaxel, used to treat breast cancer in a clinical trial, was associated with an increased risk of serious complications, resulting in the premature termination of the trial, according to a study in the May 18 issue of JAMA.
A targeted cancer drug given with low-dose chemotherapy shrank ovarian tumors and slowed progression of ovarian cancer in patients with recurrent disease, according to research findings presented by Agustin Garcia, M.D., principal investigator of the study and Director of Breast Cancer Research at the Women's Cancer Research Institute at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center.
Final results from the largest international study in the treatment of advanced stomach cancer, also known as gastric cancer, demonstrated that patients who received a Taxotere (docetaxel) Injection Concentrate-based chemotherapy regimen (Taxotere, cisplatin and 5-fluorouracil) had significantly improved overall survival rates compared to patients who received a standard treatment (cisplatin and 5- fluorouracil).
A new use of the drug Herceptin appears to offer a much more powerful treatment advantage than expected for patients with HER-2-positive breast cancer, say researchers at The University of Texas M. D. Anderson Cancer Center.
The outcome of chemotherapy treatment for acute lymphoblastic leukemia (ALL) depends not only on the acquired genetic make-up of the leukemic cells, but on genes that children inherit from their parents. This study, from investigators at St. Jude Children's Research Hospital, is published in the online edition of Blood.
Some children with a rare brain tumor that is considered almost universally fatal can be saved if they receive radiation therapy followed by tandem (given one after the other) cycles of high-dose chemotherapy.
A Johns Hopkins-led study designed to evaluate the ability of etanercept to maintain disease remissions in a serious autoimmune disorder has failed to show any benefit. Etanercept, also called Enbrel, is a common treatment for rheumatoid arthritis and other types of joint inflammation.
Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).
CuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA.
Mayo Clinic investigators have found that the medication mycophenolate mofetil is effective for managing symptoms of systemic lupus erythematosus (SLE), the most common type of lupus, for patients whose SLE does not affect the kidneys.
Dr. Olivier Feron and his team from the University of Louvain Medical School in Brussels have turned the whole concept of targeting tumour blood vessels on its head. Instead of the conventional approach of trying to starve tumour cells of the blood supply they need to grow, they are doing the opposite – opening up the tumour blood supply to allow better access for cancer drugs and more effective radiotherapy.
Cytogen Corporation today announced the presentation of new data relating to its lead therapeutic product Quadramet (samarium Sm-153 lexidronam injection) during the 36th Congress of the International Society of Pediatric Oncology (SIOP).
Cell Therapeutics, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for pixantrone, a novel anthracenedione, being investigated for the potential treatment of relapsed, aggressive non-Hodgkin's lymphoma (NHL).
Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.
According to a study conducted at The University of Texas M. D. Anderson Cancer Center, more than twice as many women with early stage, HER-2 positive breast disease who received Herceptin as part of their pre-surgery chemotherapy had their tumors completely disappear compared to like patients who received only chemotherapy.
A pair of studies at UCLA's Jonsson Cancer Center that takes laboratory science to the patients' bedside found that combining the molecularly targeted therapy Herceptin with a specific chemotherapy combination resulted in significant tumor response rates and longer relapse-free periods in women with an aggressive form of advanced breast cancer.
The study will include a basic research component to examine the roles of B and T cells, white blood cells in the immune system, in triggering lupus symptoms.
Bladder cancer is the fourth most common cancer in men and the eighth most common in women, according to the National Cancer Institute (NCI). It is expected to be diagnosed in 38,000 men and 15,000 women in the United States in 2003. Treatment is most successful when the disease is caught early.
YM BioSciences Inc., the cancer drug development company, today announced that the first patient has been dosed in its 700 patient Phase III registration trial.